About me
Mike Riley joined Veranova as Chief Executive Officer in May 2023. Mike has over 25 years of professional experience, the majority of which has been spent in the pharmaceutical contract development and manufacturing (CDMO) industry. Prior to joining Veranova, he spent 19 years at Catalent, Inc., most recently serving as President of Biotherapeutics. During his tenure at Catalent, Mike led and built Catalent’s biologics business into a leading service provider for advanced biologics modalities, including proteins, monoclonal antibodies and Antibody Drug Conjugates. Mike served in multiple executive positions at Catalent and was part of the core leadership team that transformed Catalent from its inception into an S&P 500 company. He began his career as a management consultant for Marakon Associates, providing strategic advisory to companies across multiple industries. Mike holds a B.A. degree from Duke University, and an MBA from The Wharton School, University of Pennsylvania.
